ASX Announcements

Filter by Year: 2019 2018 2017 2016
Noxopharm to expedite Veyonda Clinical Program
Appendix 4D and Half Year Accounts
Change of Director's Interest Notice - GK
Updated Share Trading Policy
FNN interview with Nox Chief Medical Officer on Interim Data
Veyonda and Radiotherapy Delivers Clinical Benefits
Appendix 3B
Appendix 4C - quarterly report for the quarter ended December 31, 2018
Principal Investigator Discusses LuPIN-1 Study

Pages:
1